Literature DB >> 2582052

Analysis of the interaction between a human high molecular weight melanoma-associated antigen and the monoclonal antibodies to three distinct antigenic determinants.

P Giacomini, P Natali, S Ferrone.   

Abstract

The restricted tissue distribution and the limited heterogeneity that appear in melanoma lesions of the high M.W. melanoma-associated antigen (HMW-MAA) suggest that this antigen may be an appropriate marker for radioimaging, and a useful target for immunotherapy in patients with melanoma. Therefore, in this study we analyzed other characteristics that are important in the selection of reagents for radioimaging and immunotherapy purposes. The affinities of the monoclonal antibodies (MoAB) 149.53, 225.28S, and 763.74T to distinct determinants of the HMW-MAA were found to be at least 1 X 10(8) mol/L. Furthermore, the effects of the concentrations of unlabeled MoAb on the dissociation rates suggest that the binding of MoAb 149.53 and 225.28S to melanoma cells (Colo 38) is preferentially bivalent, whereas that of MoAb 763.74T is preferentially univalent. These results suggest that the latter MoAb is the reagent of choice for assays that make use of soluble HMW-MAA, whereas the former two are the reagents of choice for assays with membrane-bound HMW-MAA, such as imaging with radiolabeled MoAb. The density of the HMW-MAA on cultured Colo 38 melanoma cells appears to be in the range of approximately 5 X 10(6) molecules/cell. The HMW-MAA was not susceptible to MoAb-mediated modulation under a variety of experimental conditions that included various concentrations of modulating MoAb, different incubation times, the use of an anti-mouse Ig antiserum, and the relaxation of equilibrium by diluting cells in MoAb-free medium. These results indicate that the HMW-MAA and the available corresponding MoAb meet the criteria to be reagents for radioimaging and immunotherapy in patients with melanoma.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2582052

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Binding parameters of monoclonal antibodies reacting with ovarian carcinoma ascites cells.

Authors:  M J Mattes; K O Lloyd; J L Lewis
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Immunotoxins: a promising treatment modality for metastatic melanoma?

Authors:  Karianne Risberg; Oystein Fodstad; Yvonne Andersson
Journal:  Ochsner J       Date:  2010

3.  Limited genomic heterogeneity of circulating melanoma cells in advanced stage patients.

Authors:  Carmen Ruiz; Julia Li; Madelyn S Luttgen; Anand Kolatkar; Jude T Kendall; Edna Flores; Zheng Topp; Wolfram E Samlowski; Edward McClay; Kelly Bethel; Soldano Ferrone; James Hicks; Peter Kuhn
Journal:  Phys Biol       Date:  2015-01-09       Impact factor: 2.583

4.  Human high molecular weight-melanoma-associated antigen: utility for detection of metastatic melanoma in sentinel lymph nodes.

Authors:  Yasufumi Goto; Soldano Ferrone; Takaaki Arigami; Minoru Kitago; Atsushi Tanemura; Eiji Sunami; Sandy L Nguyen; Roderick R Turner; Donald L Morton; Dave S B Hoon
Journal:  Clin Cancer Res       Date:  2008-06-01       Impact factor: 12.531

Review 5.  Melanoma biomolecules: independently identified but functionally intertwined.

Authors:  Danielle E Dye; Sandra Medic; Mel Ziman; Deirdre R Coombe
Journal:  Front Oncol       Date:  2013-09-24       Impact factor: 6.244

6.  Immunoscintigraphy and pharmacokinetics of indium-111-labeled ZME-018 monoclonal antibody in patients with malignant melanoma.

Authors:  M Koizumi; K Endo; Y Watanabe; T Saga; H Sakahara; J Konishi; Y Arano; Y Miyachi; M Kashihara-Sawami; S Imamura
Journal:  Jpn J Cancer Res       Date:  1988-08

7.  Cottonseed extracts regulate gene expression in human colon cancer cells.

Authors:  Heping Cao; Kandan Sethumadhavan; Xiaoyu Wu; Xiaochun Zeng; Lin Zhang
Journal:  Sci Rep       Date:  2022-01-20       Impact factor: 4.996

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.